Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bone Research
New bone research study findings have been published by scientists at University of Leicester
June 18th, 2009
"The secreted glycoprotein sclerostin has recently emerged as a key negative regulator of Wnt signaling in bone and has stimulated considerable interest as a potential target for therapeutics designed to treat conditions associated with low bone mass, such as osteoporosis. We have determined the structure of sclerostin, which resulted in the identification of a previously unknown binding site for heparin, suggestive of a functional role in localizing sclerostin to the surface of target cells," investigators in Leicester, the United Kingdom report. "We have also mapped the interaction site for an antibody that blocks the inhibition of Wnt signaling by sclerostin. This...
Source: Women's Health Weekly (2009-06-18)
|
